NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has decreased by 2.5% and is now trading at $11.73. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) posted its quarterly earnings data on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $5.21 million for the quarter, compared to analysts' expectations of $7.19 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 452.92%. View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

6 equities research analysts have issued 12 month price objectives for Cytokinetics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Cytokinetics' stock price to reach $22.17 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View analysts' price targets for Cytokinetics.

Media headlines about CYTK stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytokinetics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCytokinetics.

Cytokinetics saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 7,830,200 shares, a decrease of 6.1% from the February 27th total of 8,340,000 shares. Based on an average trading volume of 749,000 shares, the short-interest ratio is currently 10.5 days. Currently, 14.4% of the shares of the company are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Emergent Biosolutions (EBS), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), PPD (SDGR), PTC Therapeutics (PTCT), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), ArQule (ARQL), Agios Pharmaceuticals (AGIO), ChemoCentryx (CCXI), Axsome Therapeutics (AXSM), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), HUTCHISON CHINA/S (HCM) and Amicus Therapeutics (FOLD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Geode Capital Management LLC (1.35%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, and Credit Suisse AG. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, and Robert I Blum. View insider buying and selling activity for Cytokinetics.

CYTK stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc., and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $11.73.

Cytokinetics has a market capitalization of $697.35 million and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. View additional information about Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]